Denise Myshko | Authors


Benefit From MURANO Trial in CLL Sustained With Subsequent Therapy

December 09, 2020

An analysis from the MURANO trial showed that venetoclax in combination with rituximab led to a more than doubling of time to next treatment compared with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

PARP Inhibitors Make Advances to mCRPC Treatment Paradigm

November 05, 2020

In the treatment landscape of metastatic castration resistant prostate cancer, the introduction of PARP inhibitors as a therapeutic option has led to progress, explained Maha Hussain, MD, in a presentation during the 38th Annual Chemotherapy Foundation Symposium.